drugset / Trial / NCT04795128
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with hematologic malignancies who have failed standard treatment.
Timeline
- Start
- 2021-05-07
- Primary completion
- 2023-08-15
- Completion
- 2023-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI322 | Monoclonal antibody | — | — |